Meeting
2024 ASCO Annual Meeting
Response to RAF/MEK/ERK inhibitors in patients with RAS altered and wild-type tumors.
Authors
Mohamed Alaa Gouda
The University of Texas MD Anderson Cancer Center, Houston, TX
Mohamed Alaa Gouda , Heather Y. Lin , Lei Kang , Hung Le , Ecaterina Elena Dumbrava , Siqing Fu , Daniel D. Karp , Apostolia Maria Tsimberidou , Aung Naing , Sarina A. Piha-Paul , Paula R Pohlmann , Jordi Rodon Ahnert , Timothy A. Yap , Funda Meric-Bernstam , David S. Hong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 3099)
DOI
10.1200/JCO.2024.42.16_suppl.3099
Abstract #
3099
Poster Bd #
244
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 1/2 study of CFT1946, a novel, bifunctional degradation activating compound (BIDAC) degrader, of mutant BRAF V600 as monotherapy and in combination with trametinib, in mutant BRAF V600 solid tumors.
First Author: Meredith McKean
Poster
2023 ASCO Annual Meeting
A phase 2 basket trial of ulixertinib (BVD-523) in combination with hydroxychloroquine in patients with advanced gastrointestinal malignancies harboring MAPK pathway mutations (BVD-523-HCQ).
First Author: Andrew H. Ko
Poster
2020 ASCO Virtual Scientific Program
Phase I dose-finding study of oral ERK1/2 inhibitor LTT462 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.
First Author: Filip Janku
Poster
2018 ASCO Annual Meeting
A phase I study of LXH254 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.
First Author: Filip Janku